Stockscreener 앱 받기
13.87
8.98%
1.06
전일 마감가:
$12.81
열려 있는:
$13.04
하루 거래량:
2.10M
Relative Volume:
0.57
시가총액:
$1.54B
수익:
$631.73M
순이익/손실:
$-239.78M
주가수익비율:
-6.8663
EPS:
-2.02
순현금흐름:
$-33.45M
1주 성능:
+10.27%
1개월 성능:
+9.06%
6개월 성능:
+16.92%
1년 성능:
-35.16%
1일 변동 폭
$12.95
$14.05
1주일 범위
$11.88
$14.49
52주 변동 폭
$6.78
$24.76
10X 제노믹스 Stock (TXG) Company Profile
명칭
10 X Genomics Inc
전화
(925) 401-7300
주소
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
TXG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
13.89 | 1.53B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
278.13 | 45.26B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
69.82 | 10.57B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
63.12 | 11.58B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
89.76 | 8.00B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
35.16 | 6.01B | 906.14M | -52.62M | 89.62M | -0.3621 |
10X 제노믹스 Stock (TXG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-13 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | 개시 | Leerink Partners | Outperform |
| 2024-07-22 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-07-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-10 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-06-27 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2024-05-01 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-10 | 개시 | Barclays | Overweight |
| 2023-03-31 | 개시 | Stephens | Overweight |
| 2023-02-02 | 개시 | UBS | Neutral |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-08-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-07-25 | 개시 | Canaccord Genuity | Buy |
| 2022-07-15 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-07-15 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-09-14 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-15 | 개시 | William Blair | Outperform |
| 2020-12-02 | 개시 | Goldman | Neutral |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-07-10 | 개시 | Stifel | Buy |
| 2020-03-05 | 개시 | Guggenheim | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-07 | 개시 | BofA/Merrill | Buy |
| 2019-10-07 | 개시 | Cowen | Outperform |
| 2019-10-07 | 개시 | JP Morgan | Overweight |
| 2019-09-24 | 개시 | Evercore ISI | Outperform |
모두보기
10X 제노믹스 주식(TXG)의 최신 뉴스
10X Genomics’ SWOT analysis: genomics firm’s stock faces funding headwinds - Investing.com
Price Floor Holding on 10x Genomics Inc. — Rebound PossibleBuy Alerts With Low Risk Confirmation Noted - 선데이타임즈
Tandem Diabetes, iRhythm, agilon health, Fortrea, and 10x Genomics Shares Skyrocket and Plummet, What You Need To Know - Yahoo Finance
Tandem Diabetes, iRhythm, agilon health, Fortrea, and 10x Genomics Shares Skyrocket and Plummet, What You Need To Know | FinancialContent - FinancialContent
Does 10x Genomics Inc. offer margin of safetyFree Weekly Earnings Watchlist - thegnnews.com
10x Genomics, Inc. (NASDAQ:TXG) Q2 2025 Earnings Call Transcript - Insider Monkey
Zacks.com featured highlights include Tsakos Energy Navigation Limited, 10x Genomics, Pan American Silver, Wolverine World Wide and Interface - TradingView
Will Breakout in 10x Genomics Inc. Sustain Through Next WeekIntraday Trend Analysis for Fast Gains Released - beatles.ru
10x Genomics to Acquire Scale Biosciences - FinSMEs
10x Genomics Sees Strong Growth with Q2 Results, Strategic Acquisition, and Optimistic Outlook - AInvest
Why 10x Genomics (TXG) Is Down 6.0% After Tariff-Driven Q2 Revenue Surge and Guidance Update - simplywall.st
10x Genomics shares rise 1.71% after-hours following Q2 revenue beat and Deutsche Bank price target adjustment. - AInvest
10x Genomics: UBS maintains a 'Neutral' Rating, The Target Price is $13 - AInvest
10x Genomics: UBS maintains Neutral rating, raises PT to $13 from $12. - AInvest
10x Genomics shares fall 4.65% intraday after reporting Q2 revenue of $172.9M, below analyst estimates of $139.4M. - AInvest
10x Genomics (NASDAQ:TXG Shareholders Incur Further Losses as Stock Declines 4.8% This Week, Taking Five-year Losses to 88% - 富途牛牛
Why 10x Genomics (TXG) Stock Is Falling Today - FinancialContent
10x Genomics, Inc. SEC 10-Q Report - TradingView
10x Genomics (NASDAQ:TXG) Reports Upbeat Q2, Stock Soars - Yahoo Finance
10x Genomics Inc (TXG) Q2 2025 Earnings Call Highlights: Navigating Revenue Shifts and ... By GuruFocus - Investing.com Canada
10x Genomics Inc (TXG) Q2 2025 Earnings Call Highlights: Navigat - GuruFocus
10x Genomics Invests in the Future with Scale Biosciences Acquisition, Eyes Scalable Growth - geneonline.com
10X Genomics Outpaces Estimates And Returns To Profit - Finimize
10x Genomics (TXG) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
10x Genomics (TXG) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance
10X Genomics' Q2 revenue beats estimates - MarketScreener
10x Genomics: Q2 Earnings Snapshot - San Antonio Express-News
10x Genomics to acquire Scale Biosciences to expand single cell analysis By Investing.com - Investing.com Australia
10x Genomics to acquire Scale Biosciences to expand single cell analysis - Investing.com
Earnings Flash (TXG) 10x Genomics, Inc. Reports Q2 Revenue $172.9M, vs. FactSet Est of $139.4M - MarketScreener
(TXG) 10x Genomics, Inc. Expects Q3 Revenue Range $140.0M$144.0M - MarketScreener
10x Genomics Reports Second Quarter 2025 Financial Results – Company Announcement - Financial Times
10x Genomics To Acquire Scale Biosciences - Barchart.com
Transcript : 10x Genomics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Earnings To Watch: 10x Genomics (TXG) Reports Q2 Results Tomorrow - Yahoo Finance
10x Genomics Inc. Recovery Potential Based on Technical ToolsScalable Portfolio Growth Suggestions Released - metal.it
Is 10x Genomics Inc. a growth stock or a value stockHigh-octane investment opportunities await - Jammu Links News
What is the dividend policy of 10x Genomics Inc. stockOverwhelming profit margins - Jammu Links News
What are analysts’ price targets for 10x Genomics Inc. in the next 12 monthsFree Predictions - Jammu Links News
Is 10x Genomics Inc. stock overvalued or undervaluedDynamic profit opportunities - Jammu Links News
What catalysts could drive 10x Genomics Inc. stock higher in 2025Remarkably fast returns - Jammu Links News
What are 10x Genomics Inc. company’s key revenue driversAchieve breakthrough performance with smart picks - Jammu Links News
What is the risk reward ratio of investing in 10x Genomics Inc. stockBuild wealth with steady, reliable stocks - Jammu Links News
What institutional investors are buying 10x Genomics Inc. stockRobust investment performance - Jammu Links News
10x Genomics' (TXG) "Sell (E+)" Rating Reiterated at Weiss Ratings - MarketBeat
When is 10x Genomics Inc. stock expected to show significant growthDaily Trading Signals That Work - Jammu Links News
Options Data Show Bullish Bias in 10x Genomics Inc.Smart Money Tracking Signal Generator Activated - metal.it
Building trade automation scripts for 10x Genomics Inc.Low Risk Picks for Daily Trading Released - metal.it
10x Genomics Inc. Recovery Likely Here’s What Data ShowsFree Signals Group - beatles.ru
10x Genomics Inc. Price Targets Raised After ReboundWeekly Setup With 3x Return Potential Published - metal.it
10x Genomics Inc. Stock Lags Behind Sector BenchmarksInvestment Plan With Growth Optimization Finalized - beatles.ru
10X 제노믹스 (TXG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
10X 제노믹스 주식 (TXG) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hindson Benjamin J. | See Remarks |
May 22 '25 |
Sale |
8.30 |
7,485 |
62,120 |
448,374 |
| Taich Adam | Chief Financial Officer |
May 22 '25 |
Sale |
8.30 |
4,044 |
33,562 |
331,588 |
5.17%
자본화:
|
볼륨(24시간):